Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer

Cancer

Volumn 107, Issue 5, 2006, Pages 1093-1100

  Borden Jr , Lester S ^a   Clark, Peter E ^a   Lovato, James ^a   Hall, M Craig ^a   Stindt, Diana ^a   Harmon, Michele ^a   Mohler, Randi M ^a   Torti, Frank M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesic scale; Androgen independent prostate cancer; Chemotherapy; Hormone refractory prostate cancer; Prostate cancer; Quality of life

Indexed keywords

ADRENALIN; AMINOGLUTETHIMIDE; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DOXORUBICIN; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; MORPHINE; NARCOTIC ANALGESIC AGENT; NAVELBINE; PC SPES; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINORELBINE DITARTRATE;

ACUTE HEART INFARCTION; ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; BONE SCINTISCANNING; BRIEF PAIN INVENTORY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DYSPNEA; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART EJECTION FRACTION; HUMAN; HYPERGLYCEMIA; KAPLAN MEIER METHOD; LUNG EMBOLISM; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; STRIDOR; SURVIVAL RATE; SURVIVAL TIME; SWELLING; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT REFUSAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PAIN MEASUREMENT; PALLIATIVE CARE; PREDNISONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VINBLASTINE;

EID: 33747879139     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22078     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Gittes RF. Carcinoma of the prostate. N Engl J Med. 1991;324:236-245.
3. [No authors listed.] Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984;311:1281-1286.
4. Parmer H, Phillips RH, Lightman SL, Edwards L, Allen L, Schally AV. Randomized controlled study of orchiectomy versus long-acting D-trp-6-LHRH microcapsules in advanced prostate carcinoma. Lancet. 1985;2:1201-1205.
5. The Veteran's Administration Cooperative Urologic Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967;124:1011-1017.
6. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med. 1993;118:804-818.
7. Eisenberger MA, DeWit R, et al. A multicenter Phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC) (abstract). J Clin Oncol. 2004;22:2s.
8. Petrylak DP, Tangen C, Hussain M, et al. SWOG 99-16: randomized Phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA) (abstract). J Clin Oncol. 2004;22:2s.
9. Fields-Jones S, Koletsky A, Wilding G, et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a Phase II trial. Ann Oncol. 1999;10:1307-1310.
10. Morant R, Hsu Schmitz SF, Bernhard J, et al. Vinorelbine in androgen-independent metastatic prostatic carcinoma-a Phase II study. Eur J Cancer. 2002;38:1626-1632.
11. Oudard S, Caty A, Humblet Y, et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol. 2001;12:847-852.
12. Smith MR, Kaufman D, Oh W, et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a Phase II study. Cancer. 2000;89:1824-1828.
13. Sweeney CJ, Monaco FJ, Jung SH, et al. A Phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002;13:435-140.
14. Tralongo P, Bollina R, Aiello R, et al. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A Phase II study. Tumori. 2003;89:26-30.
15. Rubles C, Furst AJ, Sriratana P, et al. Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer. Oncol Rep. 2003;10:885-889.
16. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer. 1977;39:1940-1948.
17. DeWys WD, Bauer M, Colsky J, et al. Comparative trial of Adriamycin and 5-fluorouracil in advanced prostatic cancer-progress report. Cancer Treat Rep. 1977;61:325-328.
18. Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol. 1983;1:477-482.
19. Small EJ, Srinivas S, Egan B, et al. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol. 1996;14:1617-1625.
20. Haas NB, Manola J, Hudes G, et al. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol. 2000;23:589-592.
21. Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol. 1988;15:371-389.
22. Logothetis CJ, Chong CDK, et al. Cytotoxic chemotherapy for hormone-refractory metastatic prostate cancer. In: Johnson DE, von Eschenbach AC, editors. Systemic Therapy for Genitourinary Cancers. Chicago: Year Book Medical Publishers, Inc.; 1989:235-238.
23. Torti FM, Lum B, Freiha FS, et al. Approaches to advanced prostate cancer at Stanford University. In: Johnson DE, Logothetis CJ, von Eschenbach AC, editors. Systemic Therapy for Genitourinary Cancers. Chicago: Year Book Medical Publishers, Inc.; 1989:239-244.
24. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
25. Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745-749.
26. Rangel C, Matzkin H, Soloway MS. Experience with weekly doxorubicin (Adriamycin) in hormone-refractory Stage D2 prostate cancer. Urology. 1992;39:577-582.
27. Miller GM, Hinman F Jr. Cortisone treatment in advanced carcinoma of the prostate. J Urol. 1954;72:485-496.
28. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590-597.
29. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654-1663.
30. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
31. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 2001;19:62-71.
32. Gregurich M. Phase III study of mitoxantrone/low-dose prednisone versus low-dose prednisone alone in patients with asymptomatic hormone-refractory carcinoma of the prostate. Proc Am Soc Clin Oncol. 2000;18:1440-1450. Abstract.
33. Lacy CF, Armstrong LL, Goldman MP. Narcotic Agonists Comparative Pharmacokinetics. Drug Information Handbook, 11th ed. Hudson, OH: Lexi-Comp Inc., 2003.